Phase II neoadjuvant trial of Albumin-Bound Paclitaxel, Trastuzumab and Pertuzumab followed by anthracycline based regimens in patients with operable Her2 positive breast cancer (OMC-BC05)

被引：0
|
作者：
Iwamoto, M. [1 ]
Matsutani, A. [1 ]
Ikari, A. [1 ]
Tominaga, T. [1 ]
Maezawa, S. [1 ]
Oku, H. [1 ]
Kimura, K. [1 ]
机构：
[1] Osaka Med Coll, Breast Surg, Osaka, Japan
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P086
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [1] Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).
    Iwamoto, Mitsuhiko
    Ikari, Ayana
    Tominaga, Tomo
    Maezawa, Saki
    Sakane, Junna
    Oku, Hiroyo
    Yoshidome, Katsuhide
    Morimoto, Takashi
    Fujioka, Hiroya
    Hagihara, Seita
    Nitta, Toshikatsu
    Matsutani, Ayumi
    Kimura, Kosei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
    Kodera, A.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Sakaguchi, S.
    Yukawa, H.
    Matsuoka, A.
    Tanaka, N.
    Kamimura, M.
    Jibiki, N.
    Fujibayasi, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [3] Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)
    Futamura, Manabu
    Ishihara, Kazuhiro
    Nagao, Yasuko
    Ogiso, Atsuko
    Niwa, Yoshimi
    Nakada, Takumi
    Kawaguchi, Yoshihiro
    Ikawa, Ai
    Kumazawa, Iwao
    Mori, Ryutaro
    Kitazawa, Mai
    Hosono, Yoshiki
    Kuno, Masashi
    Kawajiri, Mana
    Nakakami, Akira
    Takeuchi, Makoto
    Morikawa, Akemi
    Tokumaru, Yoshihisa
    Katagiri, Yasuo
    Asano, Yoshimasa
    Mushika, Yoshinori
    Shimokawa, Toshio
    Matsuhasih, Nobuhisa
    BREAST CANCER, 2023, 30 (02) : 293 - 301
  • [4] Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)
    Manabu Futamura
    Kazuhiro Ishihara
    Yasuko Nagao
    Atsuko Ogiso
    Yoshimi Niwa
    Takumi Nakada
    Yoshihiro Kawaguchi
    Ai Ikawa
    Iwao Kumazawa
    Ryutaro Mori
    Mai Kitazawa
    Yoshiki Hosono
    Masashi Kuno
    Mana Kawajiri
    Akira Nakakami
    Makoto Takeuchi
    Akemi Morikawa
    Yoshihisa Tokumaru
    Yasuo Katagiri
    Yoshimasa Asano
    Yoshinori Mushika
    Toshio Shimokawa
    Nobuhisa Matsuhasih
    Breast Cancer, 2023, 30 : 293 - 301
  • [5] Phase II Neoadjuvant Trial of Anthracycline Based Regimens Followed by a Combination with Nanoparticle Almumin-Bound Paclitaxel and Trastuzumab in Patients with Operable T2-3,N0-1,Her2 Positive Breast Cancer.
    Iwamoto, M.
    Takahashi, Y.
    Kimura, K.
    Tanaka, S.
    Uchiyama, K.
    CANCER RESEARCH, 2011, 71
  • [6] Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer
    Tanaka, Satoru
    Iwamoto, Mitsuhiko
    Kimura, Kosei
    Matsunami, Nobuki
    Morishima, Hirotaka
    Yoshidome, Katsuhide
    Nomura, Takashi
    Morimoto, Takashi
    Yamamoto, Daigo
    Tsubota, Yu
    Kobayashi, Toshihiro
    Uchiyamal, Kazuhisa
    CLINICAL BREAST CANCER, 2015, 15 (03) : 191 - 196
  • [7] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Takahashi, M.
    Hayashida, T.
    Sakata, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Phase II neoadjuvant trial of nanoparticle almumin-bound paclitaxel and trastuzumab in patients with nodenegative, Her-2 positive breast cancer (OMC-BC04)
    Iwamoto, M.
    Tanaka, S.
    Koda, C.
    Kawaguchi, K.
    Terasawa, R.
    Sato, N.
    Fujioka, H.
    Kimura, K.
    Uchiyama, K.
    CANCER RESEARCH, 2017, 77
  • [9] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
    Jinno, H.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [10] Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study
    Levaggi, A.
    Poggio, F.
    Lambertini, M.
    D'Alonzo, A.
    Giraudi, S.
    Bighin, C.
    Blondeaux, E.
    Pastorino, S.
    Abate, A.
    Iacono, G.
    Vaglica, M.
    Conte, B.
    Pronzato, P.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2016, 27
12345